Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center
Adar Zinger1, David Choi1, Natalie Choi1
1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois.
Risankizumab effectively targets interleukin-23 (IL-23) for inflammatory bowel diseases. This study evaluates its real-world induction effectiveness and safety in Crohn's disease patients.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Interleukin-23 (IL-23) plays a key role in the pathogenesis of inflammatory bowel diseases (IBDs).
- Ustekinumab, targeting the shared p40 subunit of IL-23 and IL-12, was the first IL-23-targeting agent for IBD.
- Risankizumab selectively inhibits IL-23 by targeting the p19 subunit.
Purpose of the Study:
- To describe the effectiveness and safety of risankizumab during the induction period.
- To evaluate risankizumab in a real-world setting for Crohn's disease (CD).
Main Methods:
- Retrospective analysis of patients treated with risankizumab for moderately to severely active Crohn's disease.
- Assessment of clinical effectiveness and safety outcomes during the induction phase.
Main Results:
- Risankizumab demonstrated effectiveness in the induction period for Crohn's disease patients.
- The safety profile of risankizumab was evaluated in this real-world cohort.
Conclusions:
- Risankizumab is an effective and safe treatment option for the induction period in Crohn's disease.
- Real-world data support the use of risankizumab for IBD management.
More Related Videos
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
